Matching articles for "solifenacin"
Issue 1672 · March 20, 2023
Drugs for Overactive Bladder

In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with age.…

Med Lett Drugs Ther. 2023 Mar 20; 65(1672):41-5 doi:10.58347/tml.2023.1672a
In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with age. Nonpharmacologic treatment, including bladder training, urge suppression, pelvic floor muscle exercises, constipation management, modification of fluid intake, and avoidance of dietary irritants such as alcohol and caffeine, should be tried first.
Issue 1658 · September 5, 2022
A Fixed-Dose Combination of Finasteride and Tadalafil (Entadfi) for BPH (online only)

The FDA has approved Entadfi (Veru), a fixed-dose combination of the 5α-reductase inhibitor finasteride and the phosphodiesterase type 5 (PDE5) inhibitor tadalafil, for initial treatment of benign prostatic…

Med Lett Drugs Ther. 2022 Sep 5; 64(1658):e1-2
The FDA has approved Entadfi (Veru), a fixed-dose combination of the 5α-reductase inhibitor finasteride and the phosphodiesterase type 5 (PDE5) inhibitor tadalafil, for initial treatment of benign prostatic hyperplasia (BPH) in men with an enlarged prostate; use of the drug is limited to 26 weeks. Entadfi is the first 5α-reductase inhibitor/PDE5 inhibitor combination to become available in the US. Finasteride ( Proscar , and generics) and tadalafil ( Cialis , and generics) are also available separately.
Issue 1649 · May 2, 2022
Drugs for Benign Prostatic Hyperplasia

About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent…

Med Lett Drugs Ther. 2022 May 2; 64(1649):65-9
About 60% of men ≥60 years old have clinically relevant prostatic enlargement due to benign prostatic hyperplasia (BPH). The goals of treatment are to decrease lower urinary tract symptoms and to prevent disease progression and complications such as acute urinary retention. The American Urologic Association's guidelines for treatment of BPH were recently updated.
Issue 1623 · May 3, 2021 Free
Vibegron (Gemtesa) for Overactive Bladder

The FDA has approved the selective beta-3 adrenergic agonist vibegron ( Gemtesa – Urovant Sciences) for treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and…

Med Lett Drugs Ther. 2021 May 3; 63(1623):67-9
The FDA has approved the selective beta-3 adrenergic agonist vibegron ( Gemtesa – Urovant Sciences) for treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. It is the second beta-3 agonist to be approved in the US; mirabegron (Myrbetriq) was the first.
Issue 1414 · April 15, 2013
Botox for Overactive Bladder

The FDA has recently approved intradetrusor injection of onabotulinumtoxinA ( Botox – Allergan) for treatment of overactive bladder in patients who cannot tolerate or have an inadequate response to…

Med Lett Drugs Ther. 2013 Apr 15; 55(1414):31-2
The FDA has recently approved intradetrusor injection of onabotulinumtoxinA ( Botox – Allergan) for treatment of overactive bladder in patients who cannot tolerate or have an inadequate response to anticholinergic therapy. Botox is also approved by the FDA for use in detrusor overactivity associated with a neurologic condition such as multiple sclerosis or spinal cord injury, and for chronic migraine, upper limb spasticity, axillary hyperhidrosis, cervical dystonia, blepharospasm, strabismus, and cosmetic reduction of wrinkles.
Issue 1410 · February 18, 2013
Mirabegron (Myrbetriq) for Overactive Bladder

Mirabegron (mir a beg’ ron; Myrbetriq [meer BEH trick] – Astellas), a beta-3 adrenergic agonist, has been approved by the FDA for the treatment of overactive bladder. It is the first beta-3 adrenergic…

Med Lett Drugs Ther. 2013 Feb 18; 55(1410):13-5
Mirabegron (mir a beg’ ron; Myrbetriq [meer BEH trick] – Astellas), a beta-3 adrenergic agonist, has been approved by the FDA for the treatment of overactive bladder. It is the first beta-3 adrenergic agonist to be approved for any indication in the US. Mirabegron has been marketed in Japan since 2011. OnabotulinumtoxinA (Botox) was also recently approved by the FDA for treatment of overactive bladder and will be reviewed in a future issue.
Issue 1311 · May 4, 2009
Fesoterodine (Toviaz) for Overactive Bladder

The FDA has approved the marketing of fesoterodine ( Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this indication.

Med Lett Drugs Ther. 2009 May 4; 51(1311):34-5
The FDA has approved the marketing of fesoterodine ( Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this indication.
Issue 1212 · July 4, 2005
CYP3A and Drug Interactions

Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in…

Med Lett Drugs Ther. 2005 Jul 4; 47(1212):54-5
Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo .
Issue 1204 · March 14, 2005
Solifenacin and Darifenacin for Overactive Bladder

Solifenacin succinate ( VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide ( Enablex - Novartis) have been approved by the FDA for oral treatment of overactive bladder.

Med Lett Drugs Ther. 2005 Mar 14; 47(1204):23-4
Solifenacin succinate ( VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide ( Enablex - Novartis) have been approved by the FDA for oral treatment of overactive bladder.